Systematic identification of feature combinations for predicting drug response with Bayesian multi-view multi-task linear regression

Bioinformatics

Volumn 33, Issue 14, 2017, Pages i359-i368

  Ammad Ud Din, Muhammad ^a,b   Khan, Suleiman A ^a,b   Wennerberg, Krister ^a   Aittokallio, Tero ^a,b,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b AALTO UNIVERSITY   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ALGORITHM; BAYES THEOREM; BIOLOGICAL MODEL; BIOLOGY; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; NEOPLASM; PERSONALIZED MEDICINE; PROCEDURES; SIGNAL TRANSDUCTION; SOFTWARE; STATISTICAL MODEL;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BAYES THEOREM; COMPUTATIONAL BIOLOGY; HUMANS; LINEAR MODELS; MODELS, BIOLOGICAL; NEOPLASMS; PRECISION MEDICINE; SIGNAL TRANSDUCTION; SOFTWARE;

EID: 85024504091     PISSN: 13674803     EISSN: 14602059     Source Type: Journal    
DOI: 10.1093/bioinformatics/btx266     Document Type: Conference Paper

References (41)

1. Ammad-Ud Din, M. et al. (2014) Integrative and personalized QSAR analysis in cancer by Kernelized Bayesian matrix factorization. J. Chem. Inf. Model, 54, 2347-2359.
2. Ammad-Ud Din, M. et al. (2016) Drug response prediction by inferring pathway-response associations with Kernelized Bayesian matrix factorization. Bioinformatics, 32, i455-i463.
3. Barretina, J. et al. (2012) The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature, 483, 603-607.
4. Basu, A. et al. (2013) An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell, 154, 1151-1161.
5. Carpenter, B. et al. (2017) Stan: A probabilistic programming language. J. Stat. Software, 76, 1-32.
6. Carvalho, C.M. et al. (2010) The horseshoe estimator for sparse signals. Biometrika, 97, 465-480.
7. Chen, B.J. et al. (2015) Context sensitive modeling of cancer drug sensitivity. PloS One, 10, e0133850.
8. Chun, H. and Keleş, S. (2010) Sparse partial least squares regression for simultaneous dimension reduction and variable selection. J. R Stat. Soc. Ser. B (Statistical Methodology), 72, 3-25.
9. Cichonska, A. et al. (2015) Identification of drug candidates and repurposing opportunities through compound-target interaction networks. Expert Opin. Drug Discov., 10, 1-13.
10. Cortés-Ciriano, I. et al. (2015) Improved large-scale prediction of growth inhibition patterns using the NCI60 panel. Bioinformatics, 31, btv529.
11. Costello, J.C. et al. (2014) A community effort to assess and improve drug sensitivity prediction algorithms. Nat. Biotechnol., 32, 1202-1212.
12. De Niz, C. et al. (2016) Algorithms for drug sensitivity prediction. Algorithms, 9, 77.
13. Dong, Z. et al. (2015) Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection. BMC Cancer, 15, 489.
14. Fleuren, E.D. et al. (2016) The kinome'at large'in cancer. Nat. Rev. Cancer, 16, 83-98.
15. Friedman, J. et al. (2010) Regularization paths for generalized linear models via coordinate descent. J. Stat. Software, 33, 1.
16. Garnett, M.J. et al. (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature, 483, 570-575.
17. Gautam, P. et al. (2016) Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells. Mol. Cancer, 15, 1.
18. Gelman, A. et al. (2006) Prior distributions for variance parameters in hierarchical models (comment on article by browne and draper). Bayesian Anal., 1, 515-534.
19. Gelman, A. et al. (2008) A weakly informative default prior distribution for logistic and other regression models. Ann. Appl. Stat., 2, 1360-1383.
20. Gu, Z. et al. (2016) Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics, 32, 2847-2849.
21. Hoerl, A. and Kennard, R. (1988). Ridge regression, in Encyclopedia of Statistical Sciences, vol. 8.
22. Iorio, F. et al. (2016) A landscape of pharmacogenomic interactions in cancer. Cell, 166, 740-754.
23. Ishwaran, H. et al. (2008) Random survival forests. Ann. Appl. Stat., 2, 841-860.
24. Jang, I.S. et al. (2014) Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data. In: Proceedings of the Pacific Symposium. pp. 63-74. Kohala Coast, Hawaii, USA.
25. Khan, S.A. and Kaski, S. (2014) Bayesian multi-view tensor factorization. In: Joint European Conference on Machine Learning and Knowledge Discovery in Databases. pp. 656-671. Springer Berlin Heidelberg.
26. Khan, S.A. et al. (2016) Bayesian multi-tensor factorization. Machine Learn., 105, 233-253.
27. Koziczak, M. et al. (2004) Blocking of fgfr signaling inhibits breast cancer cell proliferation through downregulation of d-type cyclins. Oncogene, 23, 3501-3508.
28. Menden, M.P. et al. (2013) Machine learning prediction of cancer cell sensitivity to drugs basedongenomic and chemical properties. PLoS One, 8, e61318.
29. Ospina, J.D. et al. (2014) Random forests to predict rectal toxicity following prostate cancer radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 89, 1024-1031.
30. Riddick, G. et al. (2011) Predicting in vitro drug sensitivity using random forests. Bioinformatics, 27, 220-224.
31. Simon, N. et al. (2013) A sparse-group lasso. J. Comput. Graph. Stat., 22, 231-245.
32. Tibshirani, R. (1996) Regression shrinkage and selection via the lasso. J. R Stat. Soc. Ser. B Methodol., 58, 267-288.
33. Tuia, D. et al. (2011) Multioutput support vector regression for remote sensing biophysical parameter estimation. IEEE Geosci. Remote Sensing Lett., 8, 804-808.
34. Turner, N. and Grose, R. (2010) Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer, 10, 116-129.
35. Warde-Farley, D. et al. (2010) The genemania prediction server: biological network integration for gene prioritization and predicting gene function. Nucl. Acids Res., 38 (2), W214-W220.
36. Ware, K.E. et al. (2010) Rapidly acquired resistance to egfr tyrosine kinase inhibitors in nsclc cell lines through de-repression of fgfr2 and fgfr3 expression. PloS One, 5, e14117.
37. Yadav, B. et al. (2014) Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci. Rep., 4, 5193.
38. Yang, W. et al. (2013) Genomics of drug sensitivity in cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. Nucl. Acids Res., 41, D955-D961.
39. Zhang, H. et al. (2007) Pdgfrs are critical for pi3k/akt activation and negatively regulated by mtor. J. Clin. Invest., 117, 730-738.
40. Zhang, N. et al. (2015) Predicting anticancer drug responses using a dual-layer integrated cell line-drug network model. PLoS Comput. Biol., 11, e1004498.
41. Zou, H. and Hastie, T. (2005) Regularization and variable selection via the elastic net. J. R Stat. Soc. Ser. B (Statistical Methodology), 67, 301-320.